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Abstract 
Introduction: Prostate cancer is a heterogeneous disease, and risk stratification systems have 
been proposed to guide treatment decisions. However, significant heterogeneity remains for 
those with unfavorable-risk disease.  
Methods: This study included 3335 patients undergoing radical prostatectomy without adjuvant 
radiotherapy in the SEARCH database. High-risk patients were dichotomized into standard and 
very high-risk (VHR) groups based on primary Gleason pattern, percentage of positive biopsy 
cores (PPBC), number of NCCN high-risk factors, and stage T3b-T4 disease. Similarly, 
intermediate-risk prostate cancer was separated into favorable and unfavorable groups based on 
primary Gleason pattern, PPBC, and number of NCCN intermediate-risk factors.  
Results: Median follow-up was 78 months. Patients with VHR prostate cancer had significantly 
worse PSA relapse-free survival (PSA-RFS, P<0.001), distant metastasis (DM, P=0.004), and 
prostate cancer specific mortality (PCSM, P=0.015) in comparison to standard high-risk (SHR) 
patients in multivariable analyses. By contrast, there was no significant difference in PSA-RFS, 
DM, or PCSM between SHR and unfavorable intermediate-risk (UIR) patients. Therefore, we 
propose a novel risk stratification system: Group 1 (low-risk), Group 2 (favorable intermediate-
risk), Group 3 (UIR and SHR), and Group 4 (VHR). The c-index of this new grouping was 0.683 
for PSA-RFS and 0.800 for metastases, compared to NCCN risk groups which yield 0.666 for 
PSA-RFS and 0.764 for metastases.  
 
Conclusions: Patients classified as VHR have markedly increased rates of PSA relapse, DM, 
and PCSM in comparison to SHR patients, whereas UIR and SHR patients have similar 
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prognosis. Novel therapeutic strategies are needed for patients with VHR, likely involving 
multimodality therapy.  
 
 
 
 
 
 
INTRODUCTION 
The clinical behavior of prostate cancer is extraordinarily heterogeneous. For example, a 
significant proportion of prostate cancers have limited propensity for metastasis and can be 
safely managed without any local or systemic treatment.1,2 On the other hand, prostate cancer 
remains a leading cause of death for men worldwide due to a minority of prostate cancers that 
exhibit a lethal phenotype, with eventual evolution to a disease state that is refractory to all 
known treatments despite aggressive therapy.3,4 In order to identify where along this spectrum a 
given prostate cancer is likely to exist, risk stratification systems, based primarily on clinical and 
pathologic factors, have been developed.  
The National Comprehensive Cancer Network (NCCN) risk stratification system is one of the 
most commonly employed prostate cancer risk stratification tools.5 The NCCN system uses 
clinical tumor stage, biopsy ISUP grade group,6 and pretreatment PSA to stratify patients into 
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risk groups. Although the discriminatory ability of this classification has been validated in 
numerous studies, there remains substantial heterogeneity of outcomes within each risk group, 
especially for high risk patients.3,7,8 Therefore, several modifications have been proposed.3,7,8  
The NCCN is now incorporating a substratification of high risk prostate cancer into its guidelines 
by employing primary Gleason pattern, number of high grade cancer cores, gross seminal vesicle 
or extra-prostate organ invasion, and number of NCCN high risk factors to identify a “very high 
risk” subgroup with poor outcomes.3 However, these criteria have not been extensively validated 
in independent datasets. Moreover, the relationship of this high risk category modification to 
other proposed modifications to the NCCN system, such as the dichotomization of the 
intermediate risk group into favorable and unfavorable subgroups, is unclear.9,10 Using the 
Shared Equal Access Regional Center Hospital (SEARCH) database, we sought to validate the 
NCCN very high risk prostate cancer classification, and attempt to combine both proposed 
dichotomizations of intermediate and high risk disease, respectively, into a single unified 
system.3,9,10 
MATERIALS AND METHODS 
Materials and Methods 
Study Design 
 After obtaining Institutional Review Board approval, men who underwent radical 
prostatectomy at six Veterans Affairs Hospitals (Palo Alto, San Diego, West Los Angeles, CA; 
Augusta, GA; Durham, Asheville, NC) from 1988-2015 were combined in the Shared Equal 
Access Regional Cancer Hospital (SEARCH) database. Men with neoadjuvant therapy were not 
included. Of 5,398 men in the database, we excluded men with missing biopsy grade group 
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(n=484), PSA (n=87), clinical stage (n=334), percent of biopsy cores with cancer (n=870), race 
(n=29), pathological features (n=95), follow-up information (n=27), and men who received 
adjuvant treatment (n=137), resulting in a study population of 3,335 men.  
 Patients were grouped into five risk categories: low risk (biopsy ISUP grade group 1, 
T1a-T2a, and PSA <10ng/ml), favorable intermediate risk (FIR), unfavorable intermediate risk 
(UIR), standard high risk (SHR), very high risk (VHR). Patients defined as intermediate risk 
according to NCCN guidelines (T2b or T2c, biopsy ISUP grade group 2-3 (Gleason score 3+4 or 
4+3), or PSA 10-20ng/ml) were considered UIR if they had biopsy ISUP grade group 3 (Gleason 
score 4+3), percentage of positive biopsy cores (PPBC) ≥50%, or multiple intermediate-risk 
factors (T2b or T2c, biopsy grade group 2-3, or PSA 10-20ng/ml).5 All other intermediate risk 
patients were classified as FIR prostate cancer. Patients defined a high risk according to NCCN 
guidelines (biopsy ISUP grade group 4-5, T3-T4, or PSA ≥20ng/ml) were considered VHR if 
they had primary Gleason pattern 5, >50% positive biopsy cores, or multiple high-risk factors 
(biopsy ISUP grade group 4-5, T3-T4, or PSA ≥20ng/ml), and SHR otherwise. The criterion of 
>50% positive cores was used instead of the current VHR NCCN criterion, 5 or more cores of 
ISUP grade group 4-5 disease, for several reasons. First, PPBC has been repeatedly validated as 
an important predictor of outcome in multiple independent datasets,9,11,12 and is current used as a 
factor to distinguish favorable from unfavorable intermediate risk.9 Furthermore, the absolute 
number of cores with Gleason score ≥ 8 is highly dependent on the number of cores taken, 
whereas PPBC, being a relative measure, is independent of the number of cores taken, assuming 
oversampling of suspicious areas in not performed. Lastly, PPBC was available in our database, 
whereas absolute number of ISUP grade group 4-5 cores was not. 
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Patients were followed to determine clinical endpoints after surgery. PSA recurrence-free 
survival (PSA-RFS) was defined as a single PSA greater than 0.2 ng/ml, 2 values of 0.2 ng/ml, 
or secondary treatment for an elevated postoperative PSA. Development of distance metastases 
(DM) was determined by bone scans or other imaging. Prostate cancer-specific mortality 
(PCSM) was defined as having metastatic progressive CRPC at time of death with no obvious 
indication of another cause of death. All-cause mortality (ACM) was determined from the 
medical records.  
Statistical Analysis 
 Characteristics of VHR patients vs. all others were compared using t-tests or rank sum 
tests for continuous variables and chi-squared tests for categorical variables. The association 
between risk group (low-risk, FIR, UIR, SHR, VHR) and the clinical endpoints (PSA-RFS, DM, 
ACM) was tested using Cox proportional hazards models. Competing risks models were used to 
test the association between risk group and PCSM, with non-prostate cancer death as the 
competing risk. Multivariable models were adjusted for age, race, year of surgery, and surgical 
center. Analyses were repeated changing the reference risk group to compare patients with SHR 
to those with UIR and VHR. Then, men with UIR and SHR were combined into one group and 
compared to those with low-risk or FIR, and men with VHR were also compared to those with 
low-risk or FIR. Cumulative incidence curves were plotted for the five risk groups and each of 
the clinical endpoints. A new stratification system was created by combining groups with similar 
risk. C-indices were compared between our new risk grouping and the standard 3-tiered NCCN 
risk groups. Statistical significance was defined as P<0.05. All analyses were performed using 
Stata v14.0. 
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RESULTS:  
Baseline characteristics are summarized in Table 1. Median follow-up for the entire cohort from 
date of prostatectomy was 78 months (IQR: 40-127). For patients with NCCN intermediate risk 
disease, 654 and 968 were classified as FIR and UIR disease, respectively. For patients with 
NCCN high risk disease, 291 were classified as SHR and 314 were classified as VHR. For VHR 
patients, 237 were classified as VHR due to PPBC ≥50%. During follow-up, there were 1105 
recurrences, 125 metastases, 65 prostate cancer-related deaths, and 662 deaths due to causes 
other than prostate cancer.  
We compared PSA-RFS, DM, PCSM, and ACM rates for patients with low risk, FIR, UIR, SHR, 
and VHR disease (Figure 1, Table 2). Compared to patients with low risk disease, those with 
VHR cancers had markedly higher rates of PSA-RFS (adjusted hazard ratio (AHR)=6.30, 95% 
confidence interval (CI): 5.15-7.69, P<0.001), DM (AHR=18.4, 95% CI: 9.27-36.3, P<0.001), 
PCSM (AHR = 14.0, 95% CI: 6.08-32.3, P<0.001) and ACM (AHR = 1.65, 95% CI: 1.27-2.15, 
P<0.001) in multivariable analyses. Notably, FIR had worse PSA-RFS (AHR=1.65, 95% CI: 
1.35-2.01, P<0.001) and DM (AHR=2.42, 95% CI: 1.06, 5.50, P=0.035) in comparison to low 
risk patients, but there was no significant difference in PCSM (AHR = 2.03, 95% CI: 0.74-5.53, 
P=0.17), or OS (AHR = 1.16, 95% CI = 0.93-1.44, P=0.19) in multivariable analysis. 
Compared to those with SHR disease (Figure 1a-d, Table 3), patients with VHR cancers had 
worse PSA-RFS (AHR=1.78, 95% CI: 1.41-2.24, P<0.001), DM (AHR=2.42, 95% CI: 1.32-
4.46, P=0.004), and PCSM (AHR = 3.18, 95% CI: 1.25-8.11) in multivariable analysis. By 
contrast, there was no difference in PSA-RFS (HR=0.86, 95% CI: 0.69-1.07, P=0.19), DM (HR= 
0.68, 95% CI: 0.37-1.25, P=0.22), or PCSM (HR=0.66, 95% CI: 0.24-1.82, P=0.42) when 
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comparing UIR to SHR patients. UIR and SHR patients had similar rates of both salvage ADT 
and salvage radiotherapy utilization (Supplementary Table 1). None of these groups had 
significantly different overall survival.  
Given the similar outcomes for SHR and UIR patients, we create a 4-tiered risk stratification 
system: Group 1 (low risk), Group 2 (FIR), Group 3 (UIR and SHR), and Group 4 (VHR) 
(Figure 2). These groups had significantly different PSA-RFS, DM, and PCSM (Table 4). For 
example, Group 4 patients had significantly higher risk of PSA-RFS (HR=2.00; 95% CI: 1.69-
2.37, P<0.001), DM (HR=2.47; 95% CI: 1.64-3.73; P<0.001), and PCSM (HR=3.04; 95% CI: 
1.70-5.45; P<0.001) in comparison to Group 3 patients in multivariable analyses. Similarly, 
Group 3 patients had significantly higher risk of PSA-RFS (AHR=1.91; 95% CI: 1.61-2.27, 
P<0.001) and DM (HR=3.07; 95% CI: 1.66-5.68; P<0.001), and borderline significant difference 
in PCSM (HR=2.27; 95% CI: 1.00-5.20; P=0.052) in comparison to Group 2. These groups had 
10 year PSA-RFS rates of 76.4%, 61.6%, 44.1%, and 31.5% (P<0.001), 10 year DM rates of 
0.7%, 2.8%, 6.9%, and 16.3% (P<0.001), and 10 year PCSM of 0.3%, 1.9%, 3.3%, and 10.9% 
(P<0.001) following prostatectomy for Groups 1-4, respectively.  The c-index of this new 
grouping was 0.683 for PSA-RFS and 0.800 for metastases, compared to NCCN risk groups 
which yield 0.666 for PSA-RFS and 0.764 for metastases.  
 
DISCUSSION: 
In this study, we validated that high risk prostate cancer is a heterogeneous disease that can be 
dichotomized into SHR and VHR groups based on primary Gleason pattern, PPBC, and number 
of NCCN high risk features. These criteria, which are similar to the system now recommended 
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by NCCN guidelines,3 identify distinct clinical entities with disparate outcomes following 
prostatectomy. After adjustment for other factors in multivariable analysis, VHR patients were 
2.4 times as likely to experience DM and 3.2 times as likely to die from prostate cancer as those 
with SHR disease. We note that these differences were observed despite the fact that patients 
with VHR disease in this study were selected to undergo surgery, and thus probably were more 
likely to have organ-confined disease, lower tumor bulk, lower comorbidity, and younger age 
than those VHR patients undergoing radiation and androgen deprivation. Overall, nearly 70% of 
VHR experienced PSA relapse within 10 years of prostatectomy, with 16% experiencing DM 
and 11% having PCSM during this time period. However, it is important to note that the median 
follow-up for the VHR cohort was 78 months, and increased prostate cancer related recurrences 
and deaths are likely with longer follow-up.  
 
We also observed that SHR patients not meeting VHR criteria had no difference in PSA-RFS, 
DM, PCSM, or OS when compared to those with UIR disease. Given that SHR patients are much 
more similar to UIR patients than VHR patients, we propose modifying current NCCN criteria 
not only to separate high risk disease into SHR and VHR groups, as is currently allowed, but also 
combining UIR and SHR patients into a single risk group.  
Our results are remarkably consistent with a recent study of prostate cancer patients undergoing 
dose-escalated radiation therapy (RT) with or without androgen deprivation therapy at a high-
volume academic institution.13 As in this study, VHR patients were found to have dramatically 
worse outcomes following RT in comparison to SHR patients. Additionally, SHR and UIR 
patients undergoing RT had identical clinical outcomes, similar to what was observed in our 
surgical cohort. The consistency of these findings across independent datasets from disparate 
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practice settings and using different treatment paradigms provides strong support that these 
results may be broadly applicable to patients with localized prostate cancer, and provides 
independent validation of our results. 
 
These results have important potential implications for therapeutic recommendations. Given the 
similar outcomes for UIR and SHR prostate cancer following prostatectomy, it is likely that 
these patients will benefit from similar therapeutic paradigms. This may mean that a proportion 
of high risk patients are able to undergo risk group de-escalation, and potentially receive 
deintensified treatment regimens. For example, SHR patients undergoing definitive radiation 
may be adequately treated according to intermediate-risk paradigms, using short-term rather than 
long-term androgen deprivation therapy. Similarly, radical prostatectomy and pelvic lymph node 
dissection without adjuvant treatment may cure a substantial proportion of SHR patients. On the 
other hand, VHR prostate cancer likely will require more aggressive management strategies and 
likely neoadjuvant systemic therapy based upon pre-surgical assessments of disease 
aggressiveness. Across cancer types, the majority of the most aggressive malignancies require a 
combination of surgery, radiation, and systemic therapy to maximize the likelihood of cure. 
Extrapolating from this paradigm to VHR prostate cancer, these patients may derive benefit from 
multi-modality approaches that combine radical prostatectomy with adjuvant radiotherapy and 
concomitant androgen deprivation. However, optimal management of SHR and VHR remains 
speculative, because few randomized studies incorporating surgery have been conducted in these 
patients. Prospective evaluation of therapeutic paradigms for SHR and VHR patients, especially 
those incorporating radical prostatectomy, is warranted. 
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We note that our VHR criteria differed slightly from those endorsed by the NCCN, first proposed 
by investigators from Johns Hopkins after a systematic evaluation of prognostic factors. First, no 
patients in our study had clinical invasion of the seminal vesicle, rectum, or bladder, which are 
considered very high risk criteria. Secondly, instead of using 5 or more cores of ISUP grade 
group 4-5 disease as a criterion for VHR classification, we chose to PPBC greater than 50% as a 
VHR feature, given that this number was readily available in our database and PPBC has been 
repeatedly validated as an important predictor of outcome in multiple independent datasets.9,11,12 
Furthermore, the absolute number of cores with Gleason score ≥ 8 is highly dependent on the 
number of cores taken, whereas PPBC, being a relative measure, is independent of the number of 
cores taken, assuming oversampling of suspicious areas in not performed. It is notable that 
approximately 75% of VHR patients in our study were classified as VHR due to PPBC ≥ 50%, 
likely as a result of patients with other aggressive features being preferentially treated with 
androgen deprivation and radiation at the institutions contributing to our database. Although this 
limits to a certain degree the comparison of our results to previous studies that used biopsies with 
greater than 4 cores of Gleason 8-10 prostate cancer to define VHR disease,3 the hazard ratios we 
report for DM (HR=2.4) and PCSM (HR=3.2) when comparing the VHR and SHR groups in this 
study are similar to those observed in the original study from Johns Hopkins that proposed this 
criterion (DM: HR=2.8, PCSM: HR=3.4). This suggests that either biopsy core metric is likely to 
be useful when identifying VHR patients, given that both identify high-risk patients with high-
volume prostate cancer. However, at institutions that extensively use MRI-guided biopsy with 
oversampling suspicious areas on imaging, and the utility of PPBC or absolute number of high 
grade cores may be reduced given that it no longer provides as accurate a measure of overall 
tumor volume, and alternate metrics may be necessary. 
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Our study has several limitations that warrant further discussion. First, this is a retrospective 
study involving men treated at several VA hospitals across the country. Thus, these results are 
not necessarily applicable to all clinical practice environments or patient populations. However, 
our findings are consistent with what has been previously described for intermediate and high 
risk prostate cancer in other settings3,7-9,13-16. The follow-up for VHR patients was also 
significantly shorter than the follow-up time for other patients in the SEARCH database. This 
difference in follow-up is, in part, due to the fact that VHR patients were significantly more 
likely to be treated in recent years, likely related to national trends for increased use of 
prostatectomy in higher risk patients over the past decade.17 Additionally, the use and timing of 
salvage therapy, which is known to impact DM and PCSM,18 was not accounted for in our 
analysis. Nevertheless, we believe our study has several strengths, such as a relatively uniform 
treatment paradigm, excluding patients receiving androgen deprivation or adjuvant radiotherapy, 
a relatively large cohort, and a multi-institutional setting including numerous urologists, and we 
think that the results are robust despite their inherent limitations, especially in combination with 
similar reported results from patients undergoing radiotherapy.13 
 
In summary, we have demonstrated that high risk prostate cancer is highly heterogeneous, and 
that primary Gleason pattern, number of positive biopsies cores, and number of NCCN high risk 
factors play an integral role in distinguishing those at highest risk for adverse outcomes 
following prostatectomy. Moreover, high risk patients not meeting VHR criteria have identical 
prognosis to those with UIR disease, and we therefore suggest combining these groups both for 
prognostic and therapeutic purposes. Further advancements in risk stratification using novel 
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imaging, genomic, proteomic, and novel molecular biomarkers, will hopefully continue to 
improve our ability to risk stratify these patients in the future. 
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TABLES 
 
 
Table 1. Baseline clinical and pathologic characteristics of the dataset. 
Table 2. Comparison of outcomes among low risk, favorable intermediate risk (FIR), 
unfavorable intermediate risk (UIR), standard high risk (SHR) and very high risk (VHR) cohorts 
using Cox univariable and multivariable regression assessing PSA recurrence free survival 
(PSA-RFS), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and all cause-
mortality (ACM). CI, confidence interval. HR, hazard ratio. 
Table 3. Comparison of unfavorable intermediate risk (UIR) and very high risk (VHR) to 
standard high risk (SHR) patients using Cox regression. CI, confidence interval. HR, hazard 
ratio. 
Table 4. Multivariable pairwise comparison of proposed 4 tiered risk group system for PSA 
recurrence free survival (PSA-RFS), distant metastasis (DM), prostate cancer-specific mortality 
(PCSM), and all cause-mortality (ACM). CI, confidence interval. HR, hazard ratio. 
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Supplementary Table 1. Utilization of salvage androgen deprivation therapy (ADT) and 
salvage radiotherapy (RT) for patients with low risk, favorable intermediate risk (FIR), 
unfavorable intermediate risk (UIR), standard high risk (SHR), and very high risk (VHR) 
prostate cancer. 
FIGURES 
Figure 1. Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), 
C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for low risk, 
favorable intermediate risk (FIR), unfavorable intermediate risk (UIR), standard high risk (SHR) 
and very high risk (VHR) cohorts. 
Figure 2. Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), 
C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for proposed 4-
tier risk stratification system. 
 
Table 1. Baseline clinical and pathologic characteristics of the dataset. 
 All Others VHR P-value 
No. of Patient (%) 3021 (90.6) 314 (9.4) - 
PSA Follow-up mo, Median (IQR)* 61.3 (30.8, 106.7) 39.6 (18.1, 70.3) <0.0011 
Total Follow-up mo, Median (IQR)** 77.3 (39.4, 127.0) 52.4 (29.2, 98.7) <0.001
1 
Age, yr, Mean (SD) 61.6 (6.2) 62.9 (5.8) <0.0012 
Race   0.725
3 
White 1703 (56.4) 184 (58.6)  
Black 1225 (40.5) 120 (38.2)  
Other 93 (3.1) 10 (3.2)  
Year of Surgery, Median (IQR) 2007 (2002, 2011) 2009 (2002, 2012) <0.001
1 
Clinical T Stage, No. (%)   <0.001
3 
  T1a-c 1915 (63.5) 158 (51.8)  
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T2 83 (2.7) 8 (2.6)  
  T2a 723 (24.0) 85 (27.9)  
  T2b 162 (5.4) 34 (11.2)  
  T2c 134 (4.4) 20 (6.5)  
Biopsy Gleason Score (%)   <0.0013 
  ≤6 1493 (49.4) 28 (8.9)  
  3+4 912 (30.2) 32 (10.2)  
  4+3 408 (13.5) 22 (7.0)  
  8-10 208 (6.9) 232 (73.9)  
PSA, Median (IQR) 6.2 (4.7, 9.1) 10.3 (6.1, 24.0) <0.001
1 
Percentage Positive Biopsy Cores (%)   <0.0013 
  <50% 2207 (73.1) 32 (10.2)  
  ≥50% 814 (26.9) 282 (89.8)  
Pathological Gleason Score (%)   <0.001
3 
  ≤6 949 (31.4) 24 (7.6)  
  3+4 1267 (42.0) 70 (22.3)  
  4+3 508 (16.8) 87 (27.7)  
  8-10 297 (9.8) 133 (42.4)  
Pathological Stage (%)   <0.001
3 
T0-T2 2389 (79.1) 144 (45.9)  
T3 540 (17.9) 151 (48.1)  
T4 92 (3.0) 19 (6.0)  
Positive Surgical Margins (%) 1150 (38.1) 176 (56.1) <0.001
3 
Extracapsular Extension (%) 480 (15.9) 139 (44.3) <0.0013 
Seminar Vesicle Invasion (%) 201 (6.7) 102 (32.5) <0.001
3 
Lymph Nodes (%)   <0.0013 
No 1921 (63.6) 276 (87.9)  
Yes 34 (1.1) 26 (8.3)  
Not Done 1066 (35.3) 12 (3.8)  
Number of Lymph Nodes Removed Median 
(IQR) 
4 (2, 9) 6 (4, 11) <0.001
1 
Received Salvage ADT (%) 368 (12.2) 116 (36.9) <0.0013 
Received Salvage XRT (%) 573 (19.0) 108 (34.4) <0.001
3 
Abbreviations: SD, standard deviation; ADT, androgen-deprivation therapy; PSA, prostate-specific 
antigen; XRT, radiation therapy 
P-value calculated using 
1
rank sum test 
2
student t test 
3
chi-squared test 
*Reported among those who did not recur 
**Reported among those who did not die 
 
Table 2. Association between low risk patients vs. other categories (5 risk groups) and prostate cancer 
outcomes 
  Univariable  Multivariable* 
Au
tho
r M
an
us
cri
pt
 Events/N HR (95% CI) p-value HR (95% CI) p-value 
PSA-RFS
 
     
Low Risk 225/1108 Ref.  Ref.  
FIR  172/654 1.58 (1.30, 1.93) <0.001 1.65 (1.35, 2.01) <0.001 
UIR  400/968 2.97 (2.52, 3.51) <0.001 3.09 (2.62, 3.65) <0.001 
SHR  123/291 3.17 (2.54, 3.95) <0.001 3.33 (2.67, 4.17) <0.001 
VHR  185/314 5.57 (4.58, 6.78) <0.001 6.30 (5.15, 7.69) <0.001 
DM      
Low Risk 11/1108 Ref.  Ref.  
FIR  12/654 2.50 (1.10, 5.66) 0.029 2.42 (1.06, 5.50) 0.035 
UIR  51/968 7.59 (3.95, 14.58) <0.001 7.42 (3.86, 14.3) <0.001 
SHR  15/291 7.57 (3.47, 16.49) <0.001 7.42 (3.39, 16.2) <0.001 
VHR  36/314 17.78 (9.04, 34.96) <0.001 18.4 (9.27, 36.3) <0.001 
PCSM      
Low Risk 8/1108 Ref.  Ref.  
FIR  7/654 2.02 (0.73, 5.57) 0.175 2.03 (0.74, 5.53) 0.168 
UIR  23/968 4.75 (2.14, 10.51) <0.001 4.75 (2.14, 10.6) <0.001 
SHR  6/291 4.25 (1.47, 12.30) 0.008 4.14 (1.41, 12.2) 0.010 
VHR  21/314 14.02 (6.19, 31.76) <0.001 14.0 (6.08, 32.3) <0.001 
ACM
 
     
Low Risk 233/1108 Ref.  Ref.  
FIR  123/654 1.24 (0.99, 1.54) 0.057 1.16 (0.93, 1.44) 0.193 
UIR  183/968 1.33 (1.09, 1.61) 0.004 1.26 (1.04, 1.53) 0.020 
SHR  54/291 1.34 (0.99, 1.80) 0.055 1.26 (0.93, 1.70) 0.130 
VHR  74/314 1.74 (1.34, 2.26) <0.001 1.65 (1.27, 2.15) <0.001 
*Adjusted for: age, race, year of surgery and center. 
Abbreviation: PSA-RFS: Prostate-specific antigen recurrence-free survival; DM: distant metastasis; PCSM: 
prostate cancer specific mortality; ACM: all-cause mortality 
** Note: Out of 3335 patients, there were 1105 recurrences, 125 distant metastases, 65 death of 
prostate cancer and 667 all-cause deaths 
 
 
 
 
 
Table 3. Comparison of unfavorable intermediate risk (UIR) and very high risk (VHR) to 
standard high risk (SHR) patients using Cox regression. CI, confidence interval. HR, hazard 
ratio. 
 Univariable  Multivariable* 
 HR (95% CI) p-value HR (95% CI) p-value 
PSA-RFS
 
    
Au
tho
r M
an
us
cri
pt
UIR vs. SHR  0.94 (0.77, 1.15) 0.547 0.92 (0.75, 1.12) 0.407 
VHR vs. SHR 1.75 (1.39, 2.19) <0.001 1.86 (1.48, 2.35) <0.001 
DM
 
    
UIR vs. SHR  1.00 (0.56, 1.78) 0.991 0.98 (0.55, 1.74) 0.936 
VHR vs. SHR 2.36 (1.29, 4.31) 0.005 2.44 (1.33, 4.46) 0.004 
PCSM     
UIR vs. SHR  1.11 (0.45, 2.73) 0.823 1.12 (0.45, 2.77) 0.806 
VHR vs. SHR 3.29 (1.32, 8.22) 0.011 3.33 (1.32, 8.39) 0.011 
ACM
 
    
UIR vs. SHR  0.98 (0.72, 1.33) 0.907 0.99 (0.73, 1.34) 0.942 
VHR vs. SHR 1.30 (0.92, 1.85) 0.142 1.33 (0.93, 1.86) 0.118 
*Adjusted for: age, race, year of surgery and center. 
Abbreviation: PSA-RFS: Prostate-specific antigen recurrence-free survival; DM: distant metastasis; PCSM: 
prostate cancer specific mortality; ACM: all-cause mortality 
** Note: Out of 1573 patients, there were 708 recurrences, 102 distant metastases, 50 death of prostate 
cancer and 311 all-cause deaths 
 
 
Table 4. Multivariable pairwise comparison of proposed 4 tiered risk group system for PSA 
recurrence free survival (PSA-RFS), distant metastasis (DM), prostate cancer-specific mortality 
(PCSM), and all cause-mortality (ACM). CI, confidence interval. HR, hazard ratio. 
 
 Univariable  Multivariable* 
 HR (95% CI) p-value HR (95% CI) p-value 
PSA-RFS
 
    
Group 2 vs. Group 1 1.58 (1.30, 1.93) <0.001 1.65 (1.35, 2.01) <0.001 
Group 3 vs. Group 1 3.02 (2.58, 3.53) <0.001 3.15 (2.68, 3.69) <0.001 
Group 4 vs. Group 1 5.57 (4.58, 6.78) <0.001 6.29 (5.15, 7.69) <0.001 
Group 1 vs. Group 2 0.63 (0.52, 0.77) <0.001 0.61 (0.50, 0.74) <0.001 
Group 3 vs. Group 2 1.91 (1.61, 2.27) <0.001 1.91 (1.61, 2.27) <0.001 
Group 4 vs. Group 2 3.52 (2.86, 4.34) <0.001 3.82 (3.10, 4.71) <0.001 
DM     
Group 2 vs. Group 1 2.50 (1.10, 5.66) 0.029 2.42 (1.06, 5.50) 0.035 
Group 3 vs. Group 1 7.59 (4.00, 14.4) <0.001 7.42 (3.91, 14.1) <0.001 
Group 4 vs. Group 1 17.8 (9.04, 35.0) <0.001 18.4 (9.27, 36.3) <0.001 
Group 1 vs. Group 2 0.40 (0.18, 0.91) 0.029 0.41 (0.18, 0.94) 0.035 
Group 3 vs. Group 2 3.04 (1.64, 5.62) <0.001 3.07 (1.66, 5.68) <0.001 
Group 4 vs. Group 2 7.12 (3.70, 13.7) <0.001 7.58 (3.93, 14.6) <0.001 
PCSM
 
    
Au
tho
r M
an
us
cri
pt
Group 2 vs. Group 1 2.02 (0.73, 5.57) 0.18 2.03 (0.74, 5.54) 0.17 
Group 3 vs. Group 1 4.63 (2.13, 10.1) <0.001 4.61 (2.11, 10.1) <0.001 
Group 4 vs. Group 1 14.0 (6.19, 31.8) <0.001 14.0 (6.08, 32.3) <0.001 
Group 1 vs. Group 2 0.50 (0.18, 1.37) 0.18 0.49 (0.18, 1.35) 0.17 
Group 3 vs. Group 2 2.30 (1.01, 5.23) 0.048 2.27 (1.00, 5.20) 0.052 
Group 4 vs. Group 2 6.95 (2.95, 16.4) <0.001 6.91 (2.89, 16.5) <0.001 
ACM     
Group 2 vs. Group 1 1.24 (0.99, 1.54) 0.057 1.16 (0.93, 1.44) 0.19 
Group 3 vs. Group 1 1.33 (1.11, 1.59) 0.002 1.26 (1.05, 1.51) 0.013 
Group 4 vs. Group 1 1.74 (1.34, 2.26) <0.001 1.65 (1.27, 2.15) <0.001 
Group 1 vs. Group 2 0.81 (0.65, 1.01) 0.057 0.86 (0.69, 1.08) 0.19 
Group 3 vs. Group 2 1.07 (0.86, 1.34) 0.52 1.09 (0.87, 1.35) 0.45 
Group 4 vs. Group 2 1.41 (1.05, 1.88) 0.021 1.42 (1.07, 1.90) 0.017 
*Adjusted for: age, race, year of surgery and center. 
Abbreviation: PSA-RFS: Prostate-specific antigen recurrence-free survival; DM: distant metastasis; PCSM: 
prostate cancer specific mortality; ACM: all-cause mortality 
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